Regulatory Audit
GLP-1 Agonist Medications: A Verification Framework for Approved Drugs vs. Research Compounds
This guide walks through the official signals and database checks that distinguish FDA-approved glucagon-like peptide-1 agonist medications from gray-market peptides and unregulated research chemicals.
Why Verification Matters for GLP-1 Products
Glucagon-like peptide-1 receptor agonists have attracted significant public attention following the approval and commercial success of branded drugs in this class. That attention has also produced a secondary market of peptide products sold under names like 'semaglutide' or 'tirzepatide' through online vendors, compounding pharmacies of uncertain standing, and gray-market research-chemical suppliers. The regulatory status of these products varies widely, and the labeling does not always make that status clear.
The core verification question is straightforward: is the product in question an FDA-approved drug dispensed through a licensed pharmacy, or is it a research compound sold outside the pharmaceutical supply chain? The answer determines whether the product has passed the agency's manufacturing, purity, and safety review processes. This guide outlines the specific databases and document signals that answer that question reliably.
This is a YMYL topic. Errors in verification carry real consequences, including exposure to products of unknown purity or potency. Every claim in this guide is tied to a specific, checkable regulatory source. Readers who need clinical guidance should consult a licensed healthcare provider, not a vendor's website.
Which GLP-1 Medications Are Actually FDA-Approved?
As of the publication of this guide, the FDA has approved several GLP-1 receptor agonist branded drugs. Semaglutide is approved under the brand names Ozempic (subcutaneous injection, NDA 209637) and Wegovy (subcutaneous injection for chronic weight management, NDA 213051), as well as Rybelsus (oral tablet, NDA 213182). Tirzepatide, a dual GIP/GLP-1 receptor agonist, is approved as Mounjaro (NDA 215866) and Zepbound (NDA 217806). Older agents in this class include liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and albiglutide (Tanzeum, now discontinued).
Each of these approvals is documented in the FDA's Drugs@FDA database, which is publicly searchable at fda.gov. A legitimate approved drug will have an NDA or BLA number, an approval letter, and a current prescribing information document (the package insert) on file. If a product cannot be matched to a record in that database, it is not an approved drug, regardless of what its label says.
The approval attaches to the specific branded product and its manufacturer, not to the active ingredient name alone. A vial labeled 'semaglutide' sold by a research-chemical vendor does not inherit the approval held by Novo Nordisk for Ozempic or Wegovy. This distinction is the single most important concept in GLP-1 product verification.
How to Use FDA Databases for a Verification Check
The FDA maintains two primary public tools for drug verification. Drugs@FDA (accessible at fda.gov) allows searches by brand name, active ingredient, or application number. A confirmed approved drug will return an application record showing the sponsor, approval date, and linked labeling documents. The Orange Book (also at fda.gov) lists approved drug products with therapeutic equivalence evaluations and is particularly useful for confirming whether a generic version of a drug has been approved. As of this writing, no generic semaglutide or tirzepatide has received FDA approval.
A second check involves the National Drug Code (NDC) directory, also maintained by the FDA. Every legally marketed finished drug product in the U.S. must have an NDC number. That number appears on the product label and can be cross-referenced in the NDC directory. If a product claims to be a pharmaceutical-grade GLP-1 agent but its NDC number does not appear in the directory, or if it carries no NDC number at all, that is a significant red flag.
For compounded versions of semaglutide or tirzepatide, the regulatory picture is more complex. During periods when FDA-approved versions appear on the drug shortage list, certain state-licensed and FDA-registered compounding pharmacies may legally prepare copies. Verification of a compounding pharmacy requires checking the FDA's list of registered outsourcing facilities (Section 503B facilities) and confirming the pharmacy's license with the relevant state board of pharmacy. A compounding pharmacy that is not on either list is operating outside the verified regulatory framework.
Signals That Indicate a Research Compound, Not an Approved Drug
Research-chemical vendors typically include disclaimers stating that their products are 'for research use only' and 'not for human use.' These disclaimers are a direct signal that the product is not an approved drug. However, some vendors omit these disclaimers or bury them in fine print while using pharmaceutical-sounding language elsewhere on the page. The verification framework does not rely on vendor language; it relies on database confirmation.
Other signals associated with non-approved research compounds include: sale in lyophilized powder form requiring reconstitution by the buyer, pricing significantly below the known wholesale cost of approved branded drugs, absence of a valid NDC number on the label, no requirement for a prescription, and certificates of analysis (COAs) issued by third-party labs rather than by an FDA-registered manufacturing facility. A COA from a third-party lab may confirm the presence of a peptide, but it does not confirm pharmaceutical-grade manufacturing standards, sterility testing, or regulatory compliance.
Vendors sometimes present COAs as proof of legitimacy. A COA is a useful document for research purposes, but it is not a substitute for FDA approval. The agency's approval process includes review of manufacturing controls, clinical trial data, and post-market surveillance obligations that a single purity test cannot replicate. Treating a COA as equivalent to an NDA approval is a category error.
What the Clinical Trial Record Shows
The approved GLP-1 drugs are backed by large, registered clinical trials. The SUSTAIN and STEP trial programs for semaglutide, for example, enrolled thousands of participants across multiple Phase 3 randomized controlled trials registered on ClinicalTrials.gov. The SURMOUNT program for tirzepatide followed a similar structure. These trials are publicly searchable by NCT number on ClinicalTrials.gov and represent the evidentiary basis for the FDA's approval decisions.
Research-chemical GLP-1 peptides do not have this trial record attached to them as products. Some may share an active ingredient with an approved drug, but the specific formulation, excipients, sterility, and manufacturing process of a research compound have not undergone the same review. When a vendor cites published clinical trial data to support a research peptide, that citation describes the approved pharmaceutical form studied in the trial, not the vendor's product.
Consumers and researchers looking to understand the evidence base for GLP-1 receptor agonists can review trial registrations directly on ClinicalTrials.gov and read the published results in journals such as the New England Journal of Medicine, where the STEP and SURMOUNT trials appeared. The distinction between the evidence for the approved drug and the regulatory status of a gray-market peptide remains firm regardless of how compelling that evidence is.
Directing Verification Questions to the Right Authorities
If a reader's goal is to access an approved GLP-1 medication, the correct path runs through a licensed healthcare provider and a licensed pharmacy. The provider can confirm whether a prescription is appropriate, and the pharmacy can be verified through the state board of pharmacy's public license lookup tool. The National Association of Boards of Pharmacy (NABP) also maintains a list of accredited pharmacies through its VIPPS program.
If a reader has received a product and wants to verify its authenticity, the NDC lookup on fda.gov is the first step. Reporting suspected counterfeit or misrepresented drug products can be done through the FDA's MedWatch program. The FDA also maintains a BeSafeRx resource specifically addressing the risks of buying prescription drugs from unverified online sources.
This guide does not provide clinical advice, prescribing guidance, or any instruction on the use of any compound. Its sole purpose is to document the regulatory signals that distinguish approved medications from non-approved products. All clinical decisions belong with a licensed provider.
Frequently asked questions
Is compounded semaglutide the same as Ozempic or Wegovy?
Compounded semaglutide is not the same product as Ozempic or Wegovy and does not carry FDA approval. During periods when semaglutide appears on the FDA's drug shortage list, certain FDA-registered 503B outsourcing facilities and state-licensed compounding pharmacies may legally prepare compounded versions. However, those compounded products have not gone through the NDA review process that Ozempic (NDA 209637) and Wegovy (NDA 213051) completed. Verification of a compounding pharmacy requires checking the FDA's 503B outsourcing facility list and the relevant state board of pharmacy license database.
Can a certificate of analysis confirm that a GLP-1 peptide product is FDA-approved?
No. A certificate of analysis from a third-party laboratory can report on the purity or identity of a peptide sample, but it carries no regulatory weight regarding FDA approval. FDA approval requires a full NDA or BLA review covering clinical trial data, manufacturing controls, labeling, and post-market obligations. A COA addresses none of those elements. The only way to confirm FDA approval is to locate the product's NDA or BLA number in the Drugs@FDA database at fda.gov.
Where can someone check whether an online pharmacy selling GLP-1 products is legitimate?
Three sources are relevant. First, the National Association of Boards of Pharmacy (NABP) maintains a VIPPS accreditation list for verified internet pharmacy practice sites at nabp.pharmacy. Second, each state's board of pharmacy publishes a public license lookup tool for pharmacies operating in that state. Third, for compounding pharmacies specifically, the FDA maintains a list of registered 503B outsourcing facilities on fda.gov. A pharmacy that does not appear in any of these sources and requires no valid prescription is operating outside the verified regulatory framework.
Sources
- Wilding et al., 2021, New England Journal of Medicine (STEP 1 trial, PMID 33567185) · Phase 3 RCT for semaglutide, 1961 participants
- Jastreboff et al., 2022, New England Journal of Medicine (SURMOUNT-1, PMID 35658024) · Phase 3 RCT for tirzepatide, 2539 participants
This audit report is educational and informational content only and is not medical advice. Verification determinations reflect documentation review, not product safety or efficacy, and carry no regulatory weight. Compounds discussed are research chemicals not approved for human use outside prescribed clinical contexts. Consult a licensed clinician before making decisions about any compound.